Use of ACE inhibitors in the horse

Equine Veterinary Education

Volumn 14, Issue 6, 2002, Pages 302-303

  Pipkin, F Broughton ^a  

^a QUEEN S MEDICAL CENTRE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN; CAPTOPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; RAMIPRIL; RECEPTOR BLOCKING AGENT;

ANGIOGENESIS; CONGESTIVE HEART FAILURE; DNA POLYMORPHISM; DRUG EFFECT; DRUG MECHANISM; DRUG USE; FEEDBACK SYSTEM; HORSE DISEASE; LUNG BLOOD VESSEL; NONHUMAN; NOTE; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; TISSUE GROWTH;

EQUUS CABALLUS;

EID: 0036907337     PISSN: 09577734     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.2042-3292.2002.tb00194.x     Document Type: Note

References (6)

1. Danser, A.H. and Schalekamp, M.A. (1996) Is there an internal cardiac renin-angiotensin system? Heart 76, Suppl. 3, 28-32.
2. Davis, G.K. and Roberts, D.H. (1997) Molecular genetics of the reninangiotensin system: Implications for angiotensin II receptor blockade. Pharmacol. Ther 75, 43-50.
3. Flather, M.D., Yusuf, S., Kober, L., Pfeffer, M., Hall, A., Murray, G., Torp-Pedersen, C., Ball, S., Pogue, J., Moye, L. and Braunwald, E. (2000) Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: A systematic overview of data from individual patients. ACE-Inhibitor Myocardial Infarction Collaborative Group. Lancet 355, 1575-1581.
4. Gavras, I. and Gavras, H. (2002) Angiotensin II as a cardiovascular risk factor. J. Hum. Hypertens. 16, Suppl. 2, S2-6.
5. Niu, T., Chen, X. and Xu, X. (2002) Angiotensin converting enzyme gene insertion/deletion polymorphism and cardiovascular disease: Therapeutic implications. Drugs 62, 977-993.
6. Paul, M., Wagner, J. and Dzau, V.J. (1993) Gene expression of the renin-angiotensin system in human tissues. Quantitative analysis by the polymerase chain reaction. J. clin. Invest. 91, 2058-2064.